文献速递肝病

不限量地中海饮食与低脂饮食均显著减少肝脂肪变:一项随机对照试验

Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial.
PubMed 文献 · Hepatology · 2018-10-14

56例非酒精性脂肪性肝病患者随机接受12周盲法不限量等热量地中海饮食或低脂饮食,49例完成干预、48例纳入分析。两组肝脂肪变均显著改善且组间无差异,地中海饮食组Framingham风险评分、总胆固醇、甘油三酯和糖化血红蛋白有组内改善,低脂饮食组无。

要点

  • 不限量地中海饮食与低脂饮食均使肝脂肪变显著降低,两组间无差异。
  • 地中海饮食组Framingham风险评分、总胆固醇、甘油三酯和糖化血红蛋白有组内改善。
  • 低脂饮食组上述心血管代谢指标无组内改善。

核心结论

  • 不限量低脂饮食与地中海饮食均以相似程度改善肝脂肪变。

研究设计与样本

  • 随机对照试验,56例非酒精性脂肪性肝病患者随机接受12周盲法饮食干预(地中海饮食 vs 低脂饮食),49例完成干预,48例纳入分析。
  • 肝脂肪变通过磁共振波谱(MRS)测定。

主要发现

  • 第12周时两组肝脂肪变均显著降低(P < 0.01),组间肝脂肪减少无差异(P = 0.32),低脂饮食组平均(标准差)相对降低25.0%(±25.3%),地中海饮食组平均(标准差)相对降低32.4%(±25.5%)。
  • 两组肝酶均显著改善。
  • 体重下降幅度小且组间无差异,低脂饮食组-1.6(±2.1)kg vs 地中海饮食组-2.1(±2.5)kg(P = 0.52)。
  • 地中海饮食组观察到Framingham风险评分(FRS)、总胆固醇、血清甘油三酯(TG)和糖化血红蛋白(HbA1c)的组内改善(均P < 0.05),低脂饮食组未观察到。
  • 地中海饮食组依从性高于低脂饮食组(88% vs 64%;P = 0.048)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although diet-induced weight loss is first-line treatment for patients with nonalcoholic fatty liver disease (NAFLD), long-term maintenance is difficult. The optimal diet for improvement in either NAFLD or associated cardiometabolic risk factors, regardless of weight loss, is unknown. We examined the effect of two ad libitum isocaloric diets (Mediterranean [MD] or low fat [LF]) on hepatic steatosis (HS) and cardiometabolic risk factors. Subjects with NAFLD were randomized to a 12-week blinded dietary intervention (MD vs. LF). HS was determined by magnetic resonance spectroscopy (MRS). From a total of 56 subjects enrolled, 49 completed the intervention and 48 were included for analysis. During the intervention, subjects on the MD had significantly higher total and monounsaturated fat, but lower carbohydrate and sodium, intakes compared to LF subjects (P < 0.01). At week 12, HS had reduced significantly in both groups (P < 0.01), and there was no difference in liver fat reduction between groups (P = 0.32), with mean (SD) relative reductions of 25.0% (±25.3%) in LF and 32.4% (±25.5%) in MD. Liver enzymes also improved significantly in both groups. Weight loss was minimal and not different between groups (-1.6 [±2.1] kg in LF vs -2.1 [±2.5] kg in MD; P = 0.52). Within-group improvements in Framingham Risk Score (FRS), total cholesterol, serum triglyceride (TG), and glycated hemoglobin (HbA1c) were observed in the MD (all P < 0.05), but not with the LF diet. Adherence was higher for the MD compared to LF (88% vs. 64%; P = 0.048). Conclusion: Ad libitum low-fat and Mediterranean diets both improve HS to a similar degree.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Properzi C, O'Sullivan TA, Sherriff JL, et al. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology. 2018. PMID: 29729189. doi:10.1002/hep.30076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。